Although some studies have shown that CD86 is the dominant ligand for regulation of immune response and proliferation of regulatory T-cells (Treg) [63,64], other authors report the role of CD86+ macrophages in inflammatory response [65], and favorable prognosis in colorectal cancer and hepatocellular carcinoma possibly due to a higher degree of M1 polarization and the subsequent anti-tumor activities [66,67]. This evidence concerns the gene CD86 and hepatocellular carcinoma.